Clinical Trials
47 trialsStudy of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma, Inc.
SELECT-NK-THYM
Beijing Biotech
SOLID-NK
Beijing Biotech
EB-DUALNK-OV
Beijing Biotech
DUAL-NK RCC
Beijing Biotech
DUET-GEJ
Beijing Biotech
SELECT-2CAR
Beijing Biotech
ZUMA-4
Gilead Sciences
DUAL-MESO-NK
Beijing Biotech
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Artiva Biotherapeutics, Inc.
QUADvance
AvenCell Therapeutics, Inc.
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
Daiichi Sankyo
DUET-HCC
Beijing Biotech
DUAL-NK-NB
Beijing Biotech
DUAL-NK-BC
Beijing Biotech
DUAL-NK-PDAC
Beijing Biotech
ALPHA2
Allogene Therapeutics
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Intima Bioscience, Inc.
CheckCell-2
Intima Bioscience, Inc.
HPV16 E6 TCR T Cells for Cervical Carcinoma
TCRCure Biopharma Ltd.
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Astellas Pharma Inc
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
ARCE Therapeutics, Inc.
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
A Phase 1/2 Trial of ADI-270 in ccRCC
Adicet Therapeutics
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Artiva Biotherapeutics, Inc.
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics, INC.
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Hoffmann-La Roche
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Celularity Incorporated
ZUMA-3
Gilead Sciences
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Celgene
Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
Mustang Bio
Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
SCG Cell Therapy Pte. Ltd.
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Arog Pharmaceuticals, Inc.
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics
ZUMA-1
Gilead Sciences
ZUMA-6
Gilead Sciences
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Arog Pharmaceuticals, Inc.
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
TCR2 Therapeutics
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
Precision BioSciences, Inc.
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients
Curocell Inc.
OVSTAR
Immetacyte Ltd
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
GC Cell Corporation
Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)
Beijing Immunochina Medical Science & Technology Co., Ltd.
A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients
Seagen Inc.
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
Targazyme, Inc.